CoChat
Sign Up
Cited by 319

The DOI matches its Crossref record.

Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease: Preliminary Results

Sparks, D. Larry, Sabbagh, Marwan N., Connor, Donald J., Lopez, Jean, Launer, Lenore J., Browne, Patrick, Wasser, Dawn, Johnson-Traver, Sherry, Lochhead, Jeff, Ziolwolski, Chuck·2005·Archives of Neurology
DOI 10.1001/archneur.62.5.753
Open this paper in CoChat — free account

Abstract

Background Laboratory evidence of cholesterol-induced production of amyloid beta as a putative neurotoxin precipitating Alzheimer disease, along with epidemiological evidence, suggests that cholesterol-lowering statin drugs may favorably influence the progression of the disorder. Objective To determine if treatment with atorvastatin calcium affects the cognitive and/or behavioral decline in patients with mild to moderate Alzheimer disease. Design Pilot intention-to-treat, proof-of-concept, double-blind, placebo-controlled, randomized (1:1) trial with a 1-year exposure to once-daily atorvastatin calcium (80 mg; two 40-mg tablets) or placebo using last observation carried forward analysis of covariance as the primary method of statistical assessment. Participants Individuals with mild to moderate Alzheimer disease (Mini-Mental State Examination score of 12-28) were recruited. Of the 98 participants providing informed consent, 71 were eligible for randomization, 67 were randomized, and 63 subjects completed the 3-month visit and were considered evaluable. Main outcome measures The primary outcome measures were change in Alzheimer's Disease Assessment Scale-cognitive subscale and the Clinical Global Impression of Change Scale scores. The secondary outcome measures included scores on the Mini-Mental State Examination, Geriatric Depression Scale, the Neuropsychiatric Inventory Scale, and the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory. The tertiary ou…

Overview

Integrity signals

Registry

Crossref · 10.1001/archneur.62.5.753

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Statins are associated with decreased Aβ formation, attributed to the reduction in cholesterol which in turn regulates BACE1.

    “Statins are associated with decreased Aβ formation, attributed to the reduction in cholesterol which in turn regulates BACE1.”

    From BACE1: More than just a β‐secretase (2022) · cites this paper as [181]

Citations

Cited by

Sorted by citations

Metadata

Authors
Sparks, D. L., Sabbagh, M. N., Connor, D. J., Lopez, J., Launer, L. J., Browne, P., Wasser, D., Johnson-Traver, S., Lochhead, J., & Ziolwolski, C.
Venue
Archives of Neurology
Publisher
American Medical Association (AMA)
Published
2005-05-01
Volume
62
Issue
5
Pages
753
ISSN
0003-9942
DOI
10.1001/archneur.62.5.753
Cited by
319
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review